Coloplast A/S(DE:CBHD)
€67.48-0.48 (-0.71%)
DE:CBHD
Coloplast A/S stock drug pipeline
€67.48
At close:-0.48 (-0.71%)
Coloplast A/S (CBHD) Drug Pipeline
29 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Speedicath Compact, Standard Care | Neurogenic Bladder Dysfunction Nos | Phase IV | Completed | Quality of Life Intermittent Catheter Study | Jan 09, 2012 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Speedicath Compact, Standard Care | Phase IV | Neurogenic Bladder Dysfunction Nos | Completed | Quality of Life Intermittent Catheter Study | Jan 09, 2012 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Coloplast A/S (DE:CBHD) have in its pipeline
Coloplast A/S DE:CBHD is currently developing the following drugs: Speedicath Compact, Standard Care. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

